Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure

Chronic kidney disease (CKD) patients develop anemia because of the low kidney erythropoietin (EPO) production, thus promoting cardiovascular complications. The degree of renal insufficiency might determine the moment to start recombinant human erythropoietin (rhEPO) therapy, but the molecular basis...

ver descrição completa

Detalhes bibliográficos
Autor principal: Teixeira, Ana Margarida (author)
Outros Autores: Garrido, Patrícia (author), Santos, Paulo (author), Alves, Rui (author), Parada, Belmiro (author), Costa, Elísio (author), Almeida, Anabela (author), Teixeira-Lemos, Edite (author), Sereno, José (author), Pinto, Rui (author), Belo, Luís (author), Santos-Silva, Alice (author), Teixeira, Frederico (author), Reis, Flávio (author)
Formato: article
Idioma:eng
Publicado em: 2011
Assuntos:
Moderate chronic renal failure
rhEPO treatment
Cardio-renal protection
Proliferation
Hypertroph
Apoptosis
Texto completo:http://hdl.handle.net/10400.14/4437
País:Portugal
Oai:oai:repositorio.ucp.pt:10400.14/4437

Texto Completo

http://hdl.handle.net/10400.14/4437

Registros relacionados